AzTrials
AzTrials

Respiratory VirusesSENTINELNCT07156890

Surveillance of Respiratory Viruses in Healthcare and Animal Workers

An observational study of Respiratory Viruses, run by Erasmus Medical Center at 1 site in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Outbreaks with viruses occur continuously, and novel viruses or new variants of existing viruses can surface after a zoonotic event or human-to-human transmission. This project proposal is designed to detect early circulation of (novel) respiratory viruses in both symptomatic and asymptomatic participants, either by… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Respiratory Viruses
How many people
250 participants
Where
1 siteNetherlands
Study dates
19 Aug 2024to Aug 2029
How long will I take part?
60 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Individuals working at healthcare facilities or facilities with animals (e.g. farms, bird ringers, or slaughterhouses). We will include an average of 250 participants per year, over a maximum of 5 years. 1,000 participants will be recruited in total for the study.

Who may be able to join

  • 18 years or older
  • Health care workers with or without direct patient contact
  • Animal workers with or without direct animal contact

Who cannot join

  • <18 years

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Corine H. Geurts van Kessel, Dr contact

+31643271384

c.geurtsvankessel@erasmusmc.nl

Netherlands1 site, 1 recruiting
  • ErasmusMC

    Rotterdam, South Holland, 3015GD

    Recruiting

Other trials in Netherlands

About this study

Official title: Surveillance of Respiratory Viruses in Healthcare and Animal Workers in the Netherlands

Outbreaks with viruses occur continuously, and novel viruses or new variants of existing viruses can surface after a zoonotic event or human-to-human transmission. This project proposal is designed to detect early circulation of (novel) respiratory viruses in both symptomatic and asymptomatic participants, either by direct detection of the virus or changes in local or systemic immunity. Additionally, SENTINEL will provide information on infectivity and (protective) immune responses in viral outbreaks or vaccination campaigns.

Read the detailed description

A well-designed surveillance study in specific cohorts can serve as an early warning system for (1) the introduction of novel viruses (or variants) in the human population, (2) viral immune escape from pre-existing immunity, or (3) virus evolution into more pathogenic variants. Here, we propose prospective sampling of two sentinel groups with high-risk-of exposure to circulating respiratory viruses for the monitoring of both symptomatic and asymptomatic infections, and immune responses to those infections. Hospital staff (HCW) were shown to be good sentinels for the early detection of respiratory viruses, due to their close contact with patients (or colleagues) with respiratory symptoms. Previous studies in HCW during the COVID-19 pandemic have shown that they are a motivated study population, in which sampling at multiple time-points is feasible if the location is close to work and easily accessible. Other interesting sentinels for respiratory viruses are animal workers (AW), as they are exposed to various animal species and infectious viruses, including respiratory viruses with zoonotic potential. History has shown that most major disease outbreaks were preceded by animal-to-human transmission events that remained undetected until large scale human-to-human transmission occurred. The COVID-19 outbreak is the most recent and devastating example. Similarly, the current extensive transmission of influenza virus H5Nx is of concern and has already spilled over into humans on several occasions. Widespread transmission spillover events to mammals could allow the virus to gain mammalian adaptation. In this prospective SENTINEL study, we propose (self)-sampling of participants (starting just before the 2024 respiratory season), during symptomatic infections to identify and genomically characterize the causative respiratory virus. Follow-up visits will be planned to monitor induced local and systemic immune responses. In addition, we propose periodic sampling of participants to assess changes in local and systemic immune parameters caused by unnoticed/asymptomatic infections with respiratory viruses. Finally, participants will be invited for follow up visits after vaccination against respiratory viruses to monitor vaccine induced responses.

This proposal is unique, as we propose to establish biobanks that include paired samples from the upper respiratory tract and peripheral blood, allowing us to study both local and systemic immunity after infection and/or vaccination. More knowledge on local immunity could be crucial for future vaccine design, and application of vaccines in the respiratory tract. SENTINEL will establish a framework that facilitates early detection of viruses that would otherwise stay under the radar until surfacing due to large scale human-to-human transmission. The rapid genomic characterization and isolation of infectious virus will support rapid development of diagnostic assays, giving a head start in case of (re)emergence of a respiratory virus. Additionally, collecting clinical samples over a prolonged period will yield a valuable biobank of blood samples, respiratory tract samples and viruses, of crucial value for future research and/or (retrospective) analysis of respiratory viruses and immune responses directed against these viruses.

Keywords
healthcare workers, respiratory viruses, pandemic preparedness, virus-specific immunity, surveillance, vaccines

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07156890
Study groupRoleWhat they receive
Health care workersHospital staff with and without direct contact to patients (HCW)
Animal workersAnimal workers with direct contact to animals (AW)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Main study endpoint

    Identification of circulating respiratory viruses by targeted molecular testing in symptomatic participants

    Measured: 60 months

  2. Main study endpoint

    Identification of circulating respiratory viruses by metagenomic sequencing in symptomatic participants

    Measured: 60 months

  3. Main study endpoint

    Identification of circulating respiratory viruses by virus culture in symptomatic participants

    Measured: 60 months

  4. Main study endpoint

    Longitudinal monitoring of local immune responses, for example by, but not limited to, quantitative, qualitative and/or functional antibody assays (ELISA, VNT, PRNT) to detect changes as a proxy for asymptomatic exposure to respiratory viruses.

    Measured: 60 months

  5. Main study endpoint

    Longitudinal monitoring of systemic immune responses, for example by, but not limited to, quantitative, qualitative and/or functional antibody assays (ELISA, VNT, PRNT) to detect changes as a proxy for asymptomatic exposure to respiratory viruses.

    Measured: 60 months

Secondary outcomes (5)
  1. Secondary study endpoint

    Evaluating antibody effector function analyses, detection of virus-specific B-cell and T-cell subset analyses by flow cytometry.

    Measured: 60 months

  2. Secondary study endpoint

    Document symptoms, disease severity, disease duration and disease burden of respiratory tract infections using questionnaires

    Measured: 60 months

  3. Secondary study endpoint

    Understand virus spill-over risks between humans and animals by sampling of animal care workers

    Measured: 60 months

  4. Secondary study endpoint

    Isolate and expand rare and/or new virus (variants) variants from clinical samples by virus culture for biobanking and future research like the development of new assays or preparation of virus stocks for in vivo or in vitro studies.

    Measured: 60 months

  5. Secondary study endpoint

    Biobanking to enable retrospective analysis, for instance to identify earlier circulation in case of a (re)emerging (new) respiratory virus (variant).

    Measured: 60 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2025
  2. Study start19 Aug 2024
  3. Primary completionAug 2029 (estimated)
  4. Study completionAug 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
250 participants (estimated)
Target duration
60 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07156890
Sponsor's protocol ID
NL-005629
Acronym
SENTINEL
Status last verified
Sep 2025
First submitted
27 Aug 2025
Last updated
5 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Respiratory Viruses, run by Erasmus Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Corine H. Geurts van Kessel, Dr (+31643271384, c.geurtsvankessel@erasmusmc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Main study endpoint (time frame: 60 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in